Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Taysha Reports $39.1 Million Third-Quarter Loss as TSHA-102 Trials Continue

None

Taysha Gene Therapies (TSHA) reported a net loss of $39.1 million, or $0.10 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported no revenue during the quarter and held $422.8 million in cash and cash equivalents at period-end.

Taysha said its REVEAL pivotal and ASPIRE trials of TSHA-102 for Rett syndrome remain ongoing. The company expects topline data from the REVEAL six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.

  • Research and development expense was $28.8 million, compared with $25.7 million a year earlier.
  • General and administrative expense was $13.1 million, compared with $8.3 million a year earlier.
  • TSHA-102 was generally well tolerated across REVEAL Phase 1/2, pivotal and ASPIRE trials involving 33 patients as of the November 2026 data cutoff, with no severe treatment-related serious adverse events or dose-limiting toxicities reported.
  • The company completed a BLA-enabling PPQ manufacturing campaign for TSHA-102 that met predefined product specifications and comparability criteria.
  • Taysha expects its current cash resources to support planned operating expenses and capital requirements into the second half of 2028.

$TSHA Insider Trading Activity

TSHA Insider Trades

$TSHA insiders have traded $TSHA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $TSHA stock by insiders over the last 6 months:

  • SUKUMAR NAGENDRAN (President and Head of R&D) sold 200,000 shares for an estimated $1,248,000

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS
Receive TSHA Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$TSHA Hedge Fund Activity

We have seen 135 institutional investors add shares of $TSHA stock to their portfolio, and 67 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles